Macrogenics (MGNX) Common Equity (2012 - 2026)

Macrogenics (MGNX) has 15 years of Common Equity data on file, last reported at $21.2 million in Q1 2026.

• Common Equity for Q1 2026 came in at $21.2 million, down 73.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.2 million (down 73.21% YoY), and the FY2025 annual result was $55.6 million, down 52.1% from the prior year.
• Common Equity fell to $21.2 million in Q1 2026 per MGNX's latest filing, from $55.6 million in the prior quarter.
• Over five years, Common Equity peaked at $194.0 million in Q3 2023 and troughed at $21.2 million in Q1 2026.
• A 5-year average of $110.7 million and a median of $116.1 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2026: Common Equity jumped 57.76% in 2023, then tumbled 73.21% in 2026.
• A 5-year view of Common Equity shows it stood at $142.0 million in 2022, then increased by 7.46% to $152.6 million in 2023, then slipped by 23.95% to $116.1 million in 2024, then slumped by 52.1% to $55.6 million in 2025, then slumped by 61.87% to $21.2 million in 2026.
• Business Quant data shows MGNX's Common Equity at $21.2 million in Q1 2026, $55.6 million in Q4 2025, and $67.0 million in Q3 2025.